Phreesia Inc

Aktienanalyse zu Phreesia Inc (PHR)

$11.280

+0.351 (+3.11%)Zum Schluss

Loading chart…
Hoch
11.310
Eröffnung
10.820
Volumengewichteter Durchschnittskurs
11.14
Volumen
764.06K
Marktkap.
1.21B
Tief
10.820
Umsatz
8.51M
EV/EBITDA, TTM
9.83

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

www.phreesia.com

KI-Analyse of Phreesia Inc (PHR)

Halten

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Phreesia Inc (PHR) beträgt 12.02, verglichen mit dem 5-Jahres-Durchschnitt von 3.94.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
3.94
Aktuelles P/E
12.02
Überbewertet
193.22
Unterbewertet
-185.34

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-21.53
Aktuelles EV/EBITDA
9.83
Überbewertet
98.35
Unterbewertet
-141.41

Erwartetes KUV

Unterbewertet
5J-Durchschnitt P/S
3.61
Aktuelles P/S
1.27
Überbewertet
5.91
Unterbewertet
1.31

Alphio-AI-Kursszenarien für PHR

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%PHR

$23.17

Szenariopreis

B

Basis

Basis · 50%PHR

$22.64

Szenariopreis

B

Bärisch

Bärisch · 25%PHR

$21.67

Szenariopreis

Whales, die PHR halten

P

Pale Fire Capital SE

+ HältPHR

-1.86%

3-Monats-Rendite

Event-Zeitleiste

2026-09-02 (ET)

19:30:00

Major Indices Bounce Back as ADP Employment Data Falls Short

16:30:00

Phreesia Reports Q2 Revenue of $129.5M, Beating Expectations

2026-06-11 (ET)

14:30:00

Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B

2026-05-27 (ET)

19:50:00

WTI Crude Oil Falls Below $90, Energy Sector Worst Performer

16:30:00

Phreesia Up 12% to $10.21 After Q1 Results, Affirms Guidance

News

PHR FAQ – beantwortet von Alphio AI

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln